Trastuzumab emtansine for patients with non-small cell lung cancer positive for human epidermal growth factor receptor 2 exon-20 insertion mutations.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Human epidermal growth factor receptor 2 (HER2) mutations are present in ∼3% of patients with non-small cell lung cancer (NSCLC), with exon-20 insertions accounting for ∼90% of such HER2 mutations and having been identified as driver oncogenic alterations. Antibody-cytotoxic drug conjugates including trastuzumab deruxtecan have shown an excellent efficacy for NSCLC with HER2 mutations. We have now performed a phase II study to evaluate the efficacy of ado-trastuzumab emtansine (T-DM1) for NSCLC positive for HER2 exon-20 insertion mutations.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Eur J Cancer

Title: European journal of cancer (Oxford, England : 1990)

Publisher: Elsevier BV

ISSN (Electronic): 1879-0852

ISSN (Print): 0959-8049

Publication date (Electronic): Feb 2022

Volume: 162

Affiliations

[1 ] Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

[2 ] Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.

[3 ] Department of Pulmonary Medicine, Sendai Kousei Hospital, Sendai, Japan.

[4 ] Department of Medical Oncology, Osaka City General Hospital, Osaka, Japan.

[5 ] Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan.

[6 ] Department of Thoracic Medical Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.

[7 ] Division of Respiratory Medicine and Rheumatology, Department of Multidisciplinary Internal Medicine, Tottori University, Tottori, Japan.

[8 ] Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan.

[9 ] Center for Clinical and Translational Research, Kyushu University Hospital, Fukuoka, Japan.

[10 ] Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; Center for Clinical and Translational Research, Kyushu University Hospital, Fukuoka, Japan.

[11 ] Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. Electronic address: okamotoi@kokyu.med.kyushu-u.ac.jp.

Article

Publisher Item ID: S0959-8049(21)01241-7

DOI: 10.1016/j.ejca.2021.11.021

PubMed ID: 34959152

SO-VID: dcfd0a9a-ac88-4882-80dc-9c799de61efe

History

Keywords: Ado-trastuzumab emtansine (T-DM1),Exon-20 insertion mutation,Human epidermal growth factor receptor 2 (HER2),Next-generation sequencing,Non–small cell lung cancer (NSCLC)

Data availability:

Keywords: Ado-trastuzumab emtansine (T-DM1), Exon-20 insertion mutation, Human epidermal growth factor receptor 2 (HER2), Next-generation sequencing, Non–small cell lung cancer (NSCLC)

Comments

Comment on this article

scite_

Smart Citations

Citing PublicationsSupportingMentioningContrasting

View Citations

See how this article has been cited at scite.ai

scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.

Cited by 24

See all cited by